기사 리스트형 웹진형 타일형 FDA approves Amgen's cheaper copy of arthritis drug Humira WASHINGTON (Reuters)By Reuters Staff - The U.S. Food and Drug Administration on Friday approved a cheaper, biosimilar version of AbbVie's top-selling arthritis drug, Humira.The drug, Amjevita, known also as adalimumab-atto, is made by biotechnology company Amgen Inc and was approved to treat rhe 2016-09-24 06:27 When anti-TNF drug fails RA patients, best to try a non-TNF biologic: study NEW YORK (Reuters Health) By Megan Brooks - For patients with rheumatoid arthritis who don't mount an adequate response to a tumor necrosis factor (TNF) inhibitor, a non-TNF biologic agent might be a better next option than trying another anti-TNF drug, a new study suggests."In patients with in 2016-09-21 03:18 처음처음1끝끝
